DEA Reschedules State-Licensed Medical Marijuana to Schedule III

DEA Reschedules State-Licensed Medical Marijuana to Schedule III

On April 23, the Acting Attorney General of the U.S. Department of Justice issued a final order moving certain marijuana-related products from Schedule I to Schedule III under the Controlled Substances Act. The move is narrowly focused, but it is a meaningful shift in federal treatment of medical marijuana.Final OrderUnder the order, marijuana, marijuana extracts, and naturally derived delta‑9 THC are placed in Schedule III, but only when they a…

Feds to Regard Cannabis as Medicine: Recreational use expected to follow within months

In the face of decades of evidence that cannabis has safe and effective medical uses, the federal government moved it on Apr 23 from Schedule I, which is for drugs […]

How Schedule III Changes 280E and Banking for Cannabis Dispensaries

📋 Key Insights for Retailers 280E relief is selective. Tax benefits primarily follow the “medical lane.” Adult-use sales may remain restricted without clear operational separation. Banking won’t flip overnight. While risk profiles improve, national banks and credit card networks are waiting for formal FinCEN guidance before changing policies. Interstate commerce is still a “no.” Schedule III does not authorize moving products across state lines…

DEA Finalizes Schedule III Rule for FDA-Approved and State-Legal Medical Marijuana Products

The Drug Enforcement Administration (DEA) has published a final rule moving FDA-approved marijuana products, along with marijuana covered by state medical marijuana licenses, from Schedule I to Schedule III of the Controlled Substances Act. The rule took effect today, April 28. The order applies to FDA-approved products containing delta-9 THC derived from the marijuana plant, … Continue reading